{"url_path":"/sec/rnxt/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 EXHIBITS AND FINANCIAL STATEMENT SCHEDULES","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1574094/0001193125-26-227256-index.html","accession_number":"0001193125-26-227256","cik":"0001574094","ticker":"RNXT","issuer_name":"RenovoRx, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1574094/0001193125-26-227256-index.html","primary_entity_key":"0001574094","primary_entity_name":"RenovoRx, Inc."},"word_count":1509,"has_tables":true,"body_markdown":"ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES\n\n(a) The following documents are filed as part of this Annual Report on Form 10-K\n\n1. Financial Statements\n\nThe financial statements required to be filed in the Form 10-K/A are listed in Part IV, Item 15 of the Original Filing.\n\n \n\n2. Financial Statement Schedules\n\nAll financial statement schedules have been omitted because the required information is not applicable or is not present in amounts sufficient to require submission of the schedules, or because the information required is included in the financial statements and accompanying notes included in this Report.\n\n3. Exhibits\n\nSee “Exhibit Index” immediately preceding the signature page of this Report, which is incorporated herein by reference.\n\n48\n\n \n\nRENOVORX, INC.\n\nEXHIBIT INDEX\n\n \n\nIncorporated by Reference\n\nExhibit No.\n\nExhibit Description\n\nForm\n\nFile No.\n\nExhibit\n\nFiling Date\n\n3.1\n\n[Sixth Amended and Restated Certificate of Incorporation of RenovoRx, Inc.](https://www.sec.gov/Archives/edgar/data/1574094/000149315221021705/ex3-1.htm)\n\n8-K\n\n001-40738\n\n3.1\n\nAugust 31, 2021\n\n3.2\n\n[Amended and Restated Bylaws of RenovoRx, Inc.](https://www.sec.gov/Archives/edgar/data/1574094/000149315223032160/ex3-1.htm)\n\n8-K\n\n001-40738\n\n3.1\n\nSeptember 11, 2023\n\n4.1\n\n[Form of Private Common Stock Warrant (related to the 2020 Convertible Notes and 2021 Convertible Notes)](https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex4-1.htm)\n\n10-Q\n\n001-40738\n\n4.1\n\nNovember 15, 2021\n\n4.2\n\n[Form of Underwriter’s Warrant](https://www.sec.gov/Archives/edgar/data/1574094/000149315221018772/ex4-1.htm)\n\nS-1\n\n333-258071\n\n4.1\n\nAugust 25, 2021\n\n4.3\n\n[Form of Warrant Agent Agreement (including the terms of the Warrants)](https://www.sec.gov/Archives/edgar/data/1574094/000149315221019398/ex4-2.htm)\n\nS-1\n\n333-258071\n\n4.2\n\nAugust 25, 2021\n\n4.4\n\n[Specimen Stock Certificate evidencing the Shares of Common Stock](https://www.sec.gov/Archives/edgar/data/1574094/000149315221018772/ex4-4.htm)\n\nS-1\n\n333-258071\n\n4.4\n\nAugust 25, 2021\n\n4.5\n\n[Form of Warrant Certificate](https://www.sec.gov/Archives/edgar/data/1574094/000149315221018772/ex4-5.htm)\n\nS-1\n\n333-258071\n\n4.5\n\nAugust 25, 2021\n\n4.6\n\n[Form of Pre-Funded Common Stock Purchase Warrant](https://www.sec.gov/Archives/edgar/data/1574094/000149315223010652/ex4-1.htm)\n\n8-K\n\n001-40738\n\n4.1\n\nApril 3, 2023\n\n4.7\n\n[Form of Common Stock Purchase Warrant](https://www.sec.gov/Archives/edgar/data/1574094/000149315223010652/ex4-2.htm)\n\n8-K\n\n001-40738\n\n4.2\n\nApril 3, 2023\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.8\n\n \n\n[Form of Warrant to Purchase Common Stock Issued in January 2024 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/ex10-3.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.3\n\n \n\nJanuary 29, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.9\n\n \n\n[Form of Placement Agent Warrant Issued in January 2024 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/ex10-5.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.5\n\n \n\nJanuary 29, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.10\n\n \n\n[Form of Pre-Funded Common Stock Purchase Warrant issued in April 2024 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/ex10-2.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.2\n\n \n\nApril 15, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.11\n\n \n\n[Form of Series A Warrant to Purchase Common Stock issued in April 2024 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/ex10-3.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.3\n\n \n\nApril 15, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.12\n\n \n\n[Form of Series B Warrant to Purchase Common Stock issued in April 2024 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/ex10-4.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.4\n\n \n\nApril 15, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.13\n\n \n\n[Form of Placement Agent Warrant to Purchase Common Stock issued in April 2024 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/ex10-5.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.5\n\n \n\nApril 15, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.14\n\n \n\n[Common Stock Purchase Warrant Issued to Medical Murray, Inc., dated September 25, 2024](https://www.sec.gov/Archives/edgar/data/1574094/000149315224045137/ex4-14.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n4.14\n\n \n\nNovember 13, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.15\n\n \n\n[Form of Underwriter Warrant issued in February 2025 Public Offering](https://www.sec.gov/Archives/edgar/data/1574094/000149315225005559/ex4-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n4.1\n\n \n\nFebruary 10, 2025\n\n49\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.16\n\n \n\n[Description of Securities](https://www.sec.gov/Archives/edgar/data/1574094/000149315222008080/ex4-6.htm)\n\n \n\n10-K\n\n \n\n001-40738\n\n \n\n4.6\n\n \n\nMarch 30, 2022\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.17\n\n \n\n[Form of Pre-Funded Warrant Issued to Investors in the March 2026 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315226012058/ex4-1.htm)\n\n \n\n8-K\n\n \n\n \n\n001-40738\n\n \n\n \n\n4.1\n\n \n\n \n\nMarch 23, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.18\n\n \n\n[Form of Milestone Warrant Issued to Investors in the March 2026 Private Placement.](https://www.sec.gov/Archives/edgar/data/1574094/000149315226012058/ex4-2.htm)\n\n \n\n8-K\n\n \n\n \n\n001-40738\n\n \n\n \n\n4.2\n\n \n\nMarch 23, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.1\n\n \n\n[Amended and Restated Investor Rights Agreement, dated as of April 18, 2018](https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-1.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nNovember 15, 2021\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.2†\n\n \n\n[Amended and Restated 2021 Omnibus Equity Incentive Plan and Forms of Stock Option Grant Notice and Option Agreement](https://www.sec.gov/Archives/edgar/data/1574094/000149315222008080/ex10-2.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nAugust 14, 2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.3†\n\n \n\n[Amended and Restated Outside Director Compensation Policy](https://www.sec.gov/Archives/edgar/data/1574094/000149315224012357/ex10-3.htm)\n\n \n\n10-K\n\n \n\n001-40738\n\n \n\n10.3\n\n \n\nApril 1, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.4†\n\n \n\n[Confirmatory Offer Letter, by and between RenovoRx, Inc. and Shaun Bagai, dated November 11, 2021](https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-4.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n10.4\n\n \n\nNovember 15, 2021\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.5†\n\n \n\n[Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated January 1, 2018](https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-5.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n10.5\n\n \n\nNovember 15, 2021\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.6†\n\n \n\n[Amendment to Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated November 11, 2021](https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-6.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n \n\n10.6\n\n \n\nNovember 15, 2021\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.7†\n\n \n\n[Amendment to Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated January 25, 2022](https://www.sec.gov/Archives/edgar/data/1574094/000149315222008080/ex10-7.htm)\n\n \n\n10-K\n\n \n\n001-40738\n\n \n\n10.7\n\n \n\nMarch 30, 2022\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.8†\n\n \n\n[Amended and Restated Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Shaun Bagai, dated November 10, 2025](https://www.sec.gov/Archives/edgar/data/1574094/000149315225022304/ex10-1.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nNovember 13, 2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.9†\n\n \n\n[Amended and Restated Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Ramtin Agah, dated November 10, 2025](https://www.sec.gov/Archives/edgar/data/1574094/000149315225022304/ex10-2.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n10.2\n\n \n\nNovember 13, 2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.10†\n\n \n\n[Key Service Provider Incentive Compensation Plan](https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-9.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n10.9\n\n \n\nNovember 15, 2021\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.11†\n\n \n\n[Form of Indemnification Agreement](https://www.sec.gov/Archives/edgar/data/1574094/000149315221017463/ex10-7.htm)\n\n \n\nS-1\n\n \n\n333-258071\n\n \n\n10.7\n\n \n\nAugust 25, 2021\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.12+\n\n \n\n[Supply Agreement, dated June 5, 2025, between RenovoRx, Inc. and Medical Murray, Inc.](https://www.sec.gov/Archives/edgar/data/1574094/000164117225024020/ex10-2.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n \n\n10.2\n\n \n\nAugust 14, 2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.13†\n\n \n\n[Amended and Restated Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Ronald Kocak, dated November 10, 2025](https://www.sec.gov/Archives/edgar/data/1574094/000149315225022304/ex10-3.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n10.3\n\n \n\nNovember 13, 2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n50\n\n \n\n10.14†\n\n \n\n[Amended and Restated Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Leesa Gentry, dated November 10, 2025](https://www.sec.gov/Archives/edgar/data/1574094/000149315225022304/ex10-4.htm)\n\n \n\n10-Q\n\n \n\n001-40738\n\n \n\n10.4\n\n \n\nNovember 13, 2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.15†#\n\n \n\n[Consulting Agreement, dated February 4, 2026, by and between RenovoRx, Inc. and Mark Voll](https://www.sec.gov/Archives/edgar/data/1574094/000149315226005437/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nFebruary 6, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.16†\n\n \n\n[Form of Placement Agency Agreement by and between RenovoRx, Inc. and Roth Capital Partners, LLC, dated March 30, 2023](https://www.sec.gov/Archives/edgar/data/1574094/000149315223010652/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nApril 3, 2023\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.17†\n\n \n\n[Form of Securities Purchase Agreement](https://www.sec.gov/Archives/edgar/data/1574094/000149315223010652/ex10-2.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.2\n\n \n\nApril 3, 2023\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.18\n\n \n\n[Subscription Agreement, by and between RenovoRx, Inc. and the investors thereto](https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nJanuary 29, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.19\n\n \n\n[Offering Extension, dated January 12, 2024](https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/ex10-2.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.2\n\n \n\nJanuary 29, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.20\n\n \n\n[Placement Agent Agreement, by and between RenovoRx, Inc. and Paulson Investment Company, LLC, dated November 14, 2023](https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/ex10-4.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.4\n\n \n\nJanuary 29, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.21\n\n \n\n[Amended and Restated Offer Letter, by and between RenovoRx, Inc. and Ronald B. Kocak](https://www.sec.gov/Archives/edgar/data/1574094/000149315224005711/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nFebruary 9, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.22\n\n \n\n[Amended and Restated Offer Letter, by and between RenovoRx, Inc. and Leesa Gentry](https://www.sec.gov/Archives/edgar/data/1574094/000149315224009978/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nMarch 14, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.23\n\n \n\n[Form of Subscription Agreement (April 2024 Private Placement)](https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nApril 15, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.24†\n\n \n\n[Form of Securities Purchase Agreement in the March 2026 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315226012058/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nMarch 23, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.25†\n\n \n\n \n\n[Agah Offer Letter, dated March 24, 2026 and effective February 27, 2026, by and between RenovoRx, Inc. and Ramtin Agah](https://www.sec.gov/Archives/edgar/data/1574094/000149315226013080/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nMarch 27, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n19.1\n\n \n\n[Insider Trading Policy](https://www.sec.gov/Archives/edgar/data/1574094/000149315224012357/ex19-1.htm)\n\n \n\n10-K\n\n \n\n001-40738\n\n \n\n19.1\n\n \n\nApril 1, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n23.1\n\n \n\n[Consent of Frank, Rimerman + Co. LLP](https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/rnxt-ex23_1.htm)\n\n \n\n10-K\n\n \n\n \n\n001-40738\n\n \n\n \n\n23.1\n\n \n\n \n\nMarch, 30, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.1\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a).](rnxt-ex31_1.htm)\n\n \n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.2\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a).](rnxt-ex31_2.htm)\n\n \n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.](rnxt-ex32_1.htm)\n\n \n\nFurnished herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.](rnxt-ex32_2.htm)\n\n \n\nFurnished herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n51\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n97.1\n\n \n\n[Policy Related to Recovery of Erroneously Awarded Compensation, adopted September 7, 2023](https://www.sec.gov/Archives/edgar/data/1574094/000149315224012357/ex97-1.htm)\n\n \n\n10-K\n\n \n\n001-40738\n\n \n\n97.1\n\n \n\nApril 1, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\n \n\n \n\nInline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document\n\n \n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents\n\n \n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n104\n\n \n\nCover Page formatted as Inline XBRL and contained in Exhibit 101\n\n \n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n† Indicates management contract or compensatory plan or arrangement\n\n+ Confidential portions of this Exhibit were redacted pursuant to Item 601(b)(2) of Regulation S-K and RenovoRx, Inc. agrees to furnish supplementally to the Securities and Exchange Commission a copy of any redacted information or omitted schedule and/or exhibit upon request.\n\n# Certain information has been omitted from this exhibit pursuant to Item 601(a)(6) or Item 601(b)(10)(iv) of Regulation S-K.\n\n* The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.\n\n52\n\n \n\nSIGNATURES\n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Amendment No. 1 to its report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\nRENOVORX, INC.\n\n \n\n \n\nDate: May 15, 2026\n\n/s/ Shaun R. Bagai\n\n \n\nShaun R. Bagai\n\n \n\nChief Executive Officer\n\n \n\n \n\nDate: May 15, 2026\n\n/s/ Mark Voll\n\n \n\nMark Voll\n\n \n\nChief Financial Officer\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.\n\n \n\nSignature\n\n \n\nTitle\n\n \n\nDate\n\n \n\n \n\n \n\n \n\n \n\n/s/ Shaun R. Bagai\n\n \n\nChief Executive Officer, Director\n\n \n\nMay 15, 2026\n\nShaun R. Bagai\n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Mark Voll\n\n \n\nChief Financial Officer\n\n \n\nMay 15, 2026\n\nMark Voll\n\n \n\n(Principal Financial and Accounting Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Ramtin Agah\n\n \n\nExecutive Chairman and Chief Medical Officer\n\n \n\nMay 15, 2026\n\nRamtin Agah, M.D.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Laurence J. Marton\n\n \n\nDirector\n\n \n\nMay 15, 2026\n\nLaurence J. Marton, M.D.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Una S. Ryan\n\n \n\nDirector\n\n \n\nMay 15, 2026\n\nUna S. Ryan, O.B.E., Ph.D., D.Sc.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Kirsten Angela Macfarlane\n\n \n\nDirector\n\n \n\nMay 15, 2026\n\nKirsten Angela Macfarlane\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Robert J. Spiegel\n\n \n\nDirector\n\n \n\nMay 15, 2026\n\nRobert J. Spiegel, M.D., FACP\n\n \n\n \n\n \n\n \n\n \n\n53"}